t-1101
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2017 (NCT03195764)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase NEK2INHIBITOR
NEK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- t-1101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04685473 | Phase 1 | Jan 1, 2021 | Taivex Therapeutics Corporation |
| NCT03349073 | Phase 1 | Sep 14, 2017 | Taivex Therapeutics Corporation |
| NCT03195764 | Phase 1 | Jul 1, 2017 | Taivex Therapeutics Corporation |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Taivex Therapeutics Corporation | For profit | 3 | 3 | 1 | 2017 |
1 organizations
Page 1 / 1